セッション

Updated survival outcomes of NEJ005/TCOG0902, a randomized PII of gefitinib and chemotherapy in EGFR-mutant NSCLC

[演者] 宮内 栄作:1
[著者] 大泉 聡史:2, 湊 浩一:2, 菅原 俊一:2, 原田 敏之:2, 藤田 結花:2, 前門戸 任:2, 渡部 聡:2, 栗原 稔:3, 貫和 敏博:2
1:東北大学病院 呼吸器内科, 2:北東日本研究機構, 3:東京がん化学療法研究会

Randomized phase 1b/3 study of erlotinib plus ramucirumab(RAM) in first-line EGFR mut + Stage Ⅳ NSCLC: phase 1b safety

[演者] Katsuyuki Kiura:1
[著者] Kazuhiko Nakagawa:2, Edward B Garon:3, Luis Paz-Ares:4, Santiago Ponce:4, Jesus C Jaime:5, Oscar J Vidal:6, Ernest Nadal:7, Jingyi Liu:8, Shuang He:8, Joseph Treat:8, Rita Dalal:8, Pablo Lee:8, Martin Reck:9
1:Okayama University Hospital, Japan, 2:Kindai University School of Medicine, 3:UCLA Medical Center, 4:Hospital Doce de Octubre, 5:Hospital Virgen del Rocio, 6:Hospital Universitario La Fe, 7:Institut Catala dOncologia, 8:Eli Lilly and Company, 9:Lungen Clinic Grosshansdorf, Airway Research Center North (ARCN), German Center for Lung Research (DZL)

EGFR遺伝子変異陽性進行非扁平上皮非小細胞肺癌に対するアファチニブ+ベバシズマブ併用療法の第Ⅰ相試験

[演者] 高 遼:1
[著者] 宿谷 威仁:1, 時任 高章:2, 山田 一彦:2, 嶋田 奈緒子:1, 小山 良:1, 今村 知世:3, 星野 友昭:2, 髙橋 和久:1
1:順天堂大学医学部 呼吸器内科, 2:久留米大学医学部 呼吸器・神経・膠原病内科, 3:慶應義塾大学医学部 臨床薬理学

演題取下

Afatinib (A) plus cetuximab (C) in the treatment of patients (pts) with NSCLC: the story so far

[演者] Leora Horn:1
[著者] Jean-Charles Soria:2, Scott Gettinger:3, Emiliano Calvo:4, Egbert Smit:5, Anas Gazzah:2, William Pao:1,8, Jean Fan:6, Mahmoud Ould-Kaci:6, Yelena Y. Janjigian:7
1:Department of Medicine, Vanderbilt-Ingram Cancer Center, Nashville, TN, United States, 2:Drug Development Department, Gustave Roussy Cancer Campus and University Paris-Sud, Villejuif, France, 3:Yale University School of Medicine and Yale Cancer Center, New Haven, CT, USA, 4:Medical Oncology Division, START Madrid, Centro Integral Oncológico Clara Campal, Madrid, Spain, 5:Department of Pulmonary Diseases, VU University Medical Center, Amsterdam, The Netherlands, 6:Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, USA, 7:Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA, 8:Current affiliation: Roche Pharma Research and Early Development, Basel, Switzerland

詳細検索